LIN28B: A Potential Drug Target and Biomarker for Inflammatory Diseases

Target Name: LIN28B

NCBI ID: G389421

LIN28B

LIN28B: A Potential Drug Target and Biomarker for Inflammatory Diseases

Introduction

LIN28B, also known as protein lin-28 homolog B, is a protein that is expressed in various tissues and cells in the body. It is a key regulator of the Wnt/FGF signaling pathway, which plays a crucial role in the development and maintenance of tissues and organs during development and throughout life. LIN28B has been shown to be involved in a wide range of physiological processes, including cell signaling, migration, and invasion. In addition, LIN28B has also been implicated in the development and progression of various diseases , including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug Target Potential

The potential drug targets for LIN28B are numerous and varied. One of the primary targets of LIN28B is the regulation of cell signaling pathways, which are critical for the development and maintenance of tissues and organs during development and throughout life. LIN28B has been shown to play a key role in the regulation of the Wnt/FGF signaling pathway, which is responsible for the development and maintenance of various tissues and organs during development, including neural tube, heart, and blood vessels.

In addition to its role in cell signaling, LIN28B has also been shown to play a critical role in the regulation of cell migration and invasion. LIN28B has been shown to be involved in the regulation of the invasive potential (IP), a protein that is critical for the migration and invasion of cancer cells. Additionally, LIN28B has also been shown to be involved in the regulation of the Notch signaling pathway, which plays a critical role in the regulation of cell proliferation and survival.

Biomarker Potential

LIN28B has also been shown to be a potential biomarker for a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, LIN28B has been shown to be involved in the regulation of the development and progression of various cancers, including breast, ovarian, and colorectal cancers. Additionally, LIN28B has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Furthermore, LIN28B has also been shown to be involved in the regulation of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Additionally, LIN28B has been shown to play a critical role in the regulation of inflammation, which is a major risk factor for the development and progression of many diseases.

Conclusion

In conclusion, LIN28B is a protein that has been shown to be involved in a wide range of physiological processes and has been implicated in the development and progression of many diseases. As a result, LIN28B has the potential to be a drug target and biomarker for a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of LIN28B in these processes and to develop effective treatments.

Protein Name: Lin-28 Homolog B

Functions: Suppressor of microRNA (miRNA) biogenesis, including that of let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and sequester them in the nucleolus, away from the microprocessor complex, hence preventing their processing into mature miRNA (PubMed:22118463). Does not act on pri-miR21 (PubMed:22118463). The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state of embryonic stem cells by preventing let-7-mediated differentiation. When overexpressed, recruits ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to their terminal uridylation and degradation (PubMed:19703396). This activity might not be relevant in vivo, as LIN28B-mediated inhibition of let-7 miRNA maturation appears to be ZCCHC11-independent (PubMed:22118463). Interaction with target pre-miRNAs occurs via an 5'-GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let-7 repression (By similarity). When overexpressed, isoform 1 stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth

The "LIN28B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIN28B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets